--- title: "CONCORD HC GP (HK.2453): Reshaping the benchmark for high-quality development in social medical services with \"Healthcare + AI + Going Global\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/288998294.md" description: "Zhang Chengyu, Vice President of CONCORD HC GP, attended the 2026 High-Quality Development Forum for Social Medical Services, sharing the strategy of \"Healthcare + AI + Going Global.\" The company's proton therapy business has made significant progress, with the Proton Center at Guangzhou Taihe Oncology Hospital operating for 18 months and serving over 880 patients, with daily treatment numbers exceeding 100, marking the entry of this business into a stage of commercial maturity and demonstrating resilience across industry cycles" datetime: "2026-06-08T03:55:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288998294.md) - [en](https://longbridge.com/en/news/288998294.md) - [zh-HK](https://longbridge.com/zh-HK/news/288998294.md) generator: "portal-rs" --- # CONCORD HC GP (HK.2453): Reshaping the benchmark for high-quality development in social medical services with "Healthcare + AI + Going Global" From May 29 to 30, 2026, the "2026 Forum on High-Quality Development and Innovative Management of Social Medical Services," hosted by the China Medical Equipment Association, successfully concluded in Beijing. This conference brought together various forces, including the National Health Commission, the National Medical Insurance Administration, and relevant medical institutions, to jointly set new coordinates for industry development: the era of extensive expansion is gradually retreating, while differentiation, lean management, digital intelligence, and internationalization have become the core directions for high-quality transformation. Mr. Zhang Chengyu, Vice President of CONCORD HC GP (02453.HK), was invited to serve as the moderator for the sub-forum on "Consumer Medical Expansion and Differentiated Competition." His leading discussions and sharing of insights deeply aligned with the conference's consensus on industry transformation. This concept coincides perfectly with CONCORD HC GP's long-standing strategy of "Medical + AI + Going Global." With forward-looking layouts and solid commercialization results, CONCORD HC GP (02453.HK) has not only established authoritative discourse power in the high-end sector but also demonstrated strong resilience and long-term certainty that transcends industry cycles. The structural differentiation in the domestic medical industry is accelerating. The market space in high-value areas such as high-end oncology specialties and full-cycle health management is gradually being released to social medical services. However, most private medical institutions are constrained by insufficient technical reserves, single service models, excessive reliance on medical insurance payments, and homogeneous competition, making it difficult to adapt to the new requirements for high-quality industry development. Enterprises with core technological barriers, diversified profit models, digital operational capabilities, and international layouts are particularly scarce. As a benchmark enterprise in the field of oncology specialties, CONCORD HC GP (02453.HK) has early on laid out a high-end differentiated track, effectively avoiding the inward spiral of low-level price wars. The core supporting CONCORD HC GP (02453.HK) through cycles is its solid and continuously fulfilled high-end oncology medical business. Just before the forum, CONCORD HC GP (02453.HK) released a voluntary announcement on the Hong Kong Stock Exchange, disclosing milestone progress in proton therapy: the proton center of Guangzhou Taihe Oncology Hospital, under its umbrella, has been operational for only 18 months, serving over 880 patients, with daily treatment numbers exceeding 100. This data marks that the proton therapy business has exited the cultivation period and entered a stage of high-load, stable commercial operation. Proton therapy, as a high-threshold field—characterized by stringent qualification approvals, extremely high technical requirements, and significant capital investment—belongs to a high-end specialty that is encouraged by policies and has strong market demand. Relying on layouts in core domestic cities, CONCORD HC GP (02453.HK) has built a complete closed loop covering proton therapy, precision radiotherapy, imaging detection, postoperative rehabilitation, and health management, optimizing revenue structure while significantly enhancing operational stability and risk resistance. While solidifying its main business, the international layout further widens the gap between CONCORD HC GP and its peers. CONCORD HC GP (02453.HK) has long collaborated deeply with MD Anderson Cancer Center and Mayo Clinic, fully introducing their standardized oncology treatment processes and quality control systems; recently, it has further deepened cooperation with Mayo Clinic, benchmarking global top standards in areas such as proton therapy talent training, cross-border difficult case consultations, international quality control, and full lifecycle health management Based on this, CONCORD HC GP is actively "going overseas," opening up two-way referral channels and creating a new growth curve. According to the announcement on May 27, its proton therapy services have covered more than 20 countries and regions worldwide, with patient ages ranging from 13 months to 91 years old, strongly demonstrating the global applicability of its technical solutions and exceptional clinical risk control capabilities. With a solid foundation of international cooperation, CONCORD HC GP has successfully attracted a large number of high-net-worth clients and commercial insurance groups globally, steadily increasing the proportion of self-paid and commercial insurance income, effectively alleviating the pressure of medical insurance reimbursement, and significantly outperforming peers in terms of profit quality and development resilience. At the same time, AI technology provides solid support for "medical + going overseas." Unlike the industry's common shallow information transformation, CONCORD HC GP (02453.HK) has achieved deep application of AI technology in scenarios such as proton target area positioning, tumor imaging diagnosis, radiotherapy planning, full-course management, and in-hospital operational control. Internally, AI enhances diagnostic accuracy and operational efficiency while reducing marginal costs; externally, AI breaks geographical limitations, broadens incremental customer sources nationwide and overseas, and forms a replicable standardized operational model, providing a technical foundation for overseas business implementation and achieving dual empowerment of "main business efficiency improvement and incremental expansion." The information released from the forum indicates that the specialization of high-end services, lean operations, digital development, and international layout have become irreversible trends, with industry resources accelerating towards leading enterprises with core barriers. With the three-dimensional synergy of "medical + AI + going overseas," CONCORD HC GP (02453.HK) fully aligns with the development direction of social medical services in the new era. As the domestic demand for high-end oncology medical services continues to be released, the scale growth of proton business, and the orderly advancement of overseas layout, the future performance growth path of CONCORD HC GP (02453.HK) is clear, making it a rare high-certainty investment target in the social medical service sector, expected to continuously create long-term stable investment returns for shareholders ### Related Stocks - [02453.HK](https://longbridge.com/en/quote/02453.HK.md) ## Related News & Research - [12:20 ETMemorialCare Rehabilitation Institute at Long Beach Medical Center Earns Exemplary Three-Year CARF Accreditation for Eighth Consecutive Time](https://longbridge.com/en/news/297939929.md) - [13:13 ETSalesSparx and Augment Launch SAMI.ai, Putting 10,000+ Hours of Healthcare Sales Intelligence to Work on Every Deal](https://longbridge.com/en/news/297681967.md) - [22:00 ETCarestream Healthcare International mejora el detector DRX LC](https://longbridge.com/en/news/297978867.md) - [Worldwide Healthcare Trust estimates Sept. 1 NAV at 414.74p per share (cum income)](https://longbridge.com/en/news/297798173.md) - [20:53 ETCalifornia Hosts 34th Annual Recovery Happens at State Capitol on September 2](https://longbridge.com/en/news/297713454.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**